Literature DB >> 19297102

A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women.

Mary C Tierney1, Paul Oh, Rahim Moineddin, Ellen M Greenblatt, W Gary Snow, Rory H Fisher, John Iazzetta, Peter St George Hyslop, Neil J MacLusky.   

Abstract

We examined whether estradiol and norethindrone hormone therapy (HT) prevented decline in delayed verbal recall in older women with normal to mildly impaired memory functioning. This was a 2-year, randomized, double-blind, placebo-controlled trial of 142 women aged 61-87, randomly assigned to receive 1 mg 17-beta estradiol daily and 0.35 mg norethindrone 3 days/week or daily placebo for 2 years. The primary outcome was short-delay verbal recall of the California Verbal Learning Test (CVLT). To look for differences in response to HT by baseline short-delay recall, we examined the primary outcome in participants grouped according to whether their baseline scores were below average for the age group or greater than or equal to this score and according to whether they met criteria for Mild Cognitive Impairment (MCI) or not. 133 women completed 1 year of the trial and 128 completed 2 years. Prespecified covariates in all repeated measures analyses of covariance (RANCOVA) included age, education, APOE epsilon4, and prior HT use. RANCOVA showed no overall significant treatment effects at year 1 or year 2. After testing for an interaction, which was significant (p=0.02), we found that women in the HT group who scored at or above the average showed significantly less decline than the placebo group in short-delay verbal recall after 1 year, p=0.007 and 2 years, p=0.01. No treatment effects were found in women below the average in either year. When grouped according to whether the participant met criteria for MCI, the interaction between treatment group and MCI subgroup was not significant. These results suggest that benefits of estrogen exposure may be limited to those with average to above average scores on the delayed verbal recall. HT dose and formulation may have contributed to these beneficial outcomes. Replication is warranted before recommendations can be made in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19297102     DOI: 10.1016/j.psyneuen.2009.02.009

Source DB:  PubMed          Journal:  Psychoneuroendocrinology        ISSN: 0306-4530            Impact factor:   4.905


  22 in total

Review 1.  Mild cognitive impairment and dementia: the importance of modifiable risk factors.

Authors:  Thorleif Etgen; Dirk Sander; Horst Bickel; Hans Förstl
Journal:  Dtsch Arztebl Int       Date:  2011-11-04       Impact factor: 5.594

Review 2.  Perimenopause and cognition.

Authors:  Gail A Greendale; Carol A Derby; Pauline M Maki
Journal:  Obstet Gynecol Clin North Am       Date:  2011-09       Impact factor: 2.844

3.  Summary of the National Institute on Aging-sponsored conference on depressive symptoms and cognitive complaints in the menopausal transition.

Authors:  Pauline M Maki; Ellen W Freeman; Gail A Greendale; Victor W Henderson; Paul A Newhouse; Peter J Schmidt; Nelda F Scott; Carol A Shively; Claudio N Soares
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

4.  Impact of continuous versus discontinuous progesterone on estradiol regulation of neuron viability and sprouting after entorhinal cortex lesion in female rats.

Authors:  Anna M Barron; Meghan A Brown; Todd E Morgan; Christian J Pike
Journal:  Endocrinology       Date:  2014-12-16       Impact factor: 4.736

5.  Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.

Authors:  Nicola Coley; Adeline Gallini; Sandrine Andrieu
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

6.  The endocrine-brain-aging triad where many paths meet: female reproductive hormone changes at midlife and their influence on circuits important for learning and memory.

Authors:  Stephanie V Koebele; Heather A Bimonte-Nelson
Journal:  Exp Gerontol       Date:  2016-12-13       Impact factor: 4.032

7.  Differences in verbal memory performance in postmenopausal women receiving hormone therapy: 17β-estradiol versus conjugated equine estrogens.

Authors:  Tonita E Wroolie; Heather A Kenna; Katherine E Williams; Bevin N Powers; Megan Holcomb; Anna Khaylis; Natalie L Rasgon
Journal:  Am J Geriatr Psychiatry       Date:  2011-09       Impact factor: 4.105

Review 8.  Long-term hormone therapy for perimenopausal and postmenopausal women.

Authors:  Jane Marjoribanks; Cindy Farquhar; Helen Roberts; Anne Lethaby; Jasmine Lee
Journal:  Cochrane Database Syst Rev       Date:  2017-01-17

9.  Effects of Hormone Therapy on List and Story Recall in Post-Menopausal Women.

Authors:  Beth A Ober; Gregory K Shenaut; Sandra L Taylor
Journal:  Exp Aging Res       Date:  2019-04-25       Impact factor: 1.645

Review 10.  Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies.

Authors:  Pauline M Maki
Journal:  Menopause       Date:  2013-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.